Cardiovascular Disease Treatment Articles & Analysis
14 news found
” “For almost thirty years, there has been no innovative treatment approved to address the high risk of kidney disease progression in adults with chronic kidney disease and type 1 diabetes. ...
ByBayer AG
Kerendia is now indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. ...
ByBayer AG
These patients are in need of treatment options that can both delay kidney disease progression and reduce the risk of cardiovascular events,” said Dr. ...
ByBayer AG
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
Reflecting the positive data from the pivotal Phase III FIGARO-DKD study on the reduction of the risk of cardiovascular events, the U.S.-label update announced today reaffirms Kerendia as a fundamental pillar in the treatment algorithm to improve outcomes in patients with chronic kidney disease associated with type 2 ...
ByBayer AG
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
“We look forward to providing patients and physicians in Japan with a new treatment option to delay kidney disease progression and reduce the risk of cardiovascular events. ...
ByBayer AG
CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. ...
ByBayer AG
These patients have a critical need for treatment options that can delay kidney disease progression and reduce the risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...
ByBayer AG
The initiation of the Phase III FIONA study (FInerenone for the treatment of children with chrOnic kidNey disease and proteinuriA) builds upon the robust Phase III results from the FIDELIO-DKD and FIGARO-DKD studies which evaluated the effects of finerenone versus placebo on top of standard of care across a broad range of disease severity, on ...
ByBayer AG
About Cardiology at Bayer Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of ...
ByBayer AG
CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. ...
ByBayer AG
BOSTON – Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, today announced $8 Million in Series A financing led by MedTex Ventures and Global Health Impact Fund. ...
ByElucid
The study was conducted in approximately 3,600 patients with moderate to very severe COPD and cardiovascular disease and / or risk factors. ASCENT was unique in that 48% of patients enrolled had at least one documented previous cardiovascular event while 96% of patients included had at least two atherothrombotic risk factors. ...